NO993275D0 - FremgangsmÕte ved terapeutisk administrering av anti-CD40L-forbindelser - Google Patents

FremgangsmÕte ved terapeutisk administrering av anti-CD40L-forbindelser

Info

Publication number
NO993275D0
NO993275D0 NO993275A NO993275A NO993275D0 NO 993275 D0 NO993275 D0 NO 993275D0 NO 993275 A NO993275 A NO 993275A NO 993275 A NO993275 A NO 993275A NO 993275 D0 NO993275 D0 NO 993275D0
Authority
NO
Norway
Prior art keywords
therapeutic administration
cd40l compounds
cd40l
compounds
administering anti
Prior art date
Application number
NO993275A
Other languages
English (en)
Other versions
NO993275L (no
Inventor
Susan L Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO993275D0 publication Critical patent/NO993275D0/no
Publication of NO993275L publication Critical patent/NO993275L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO993275A 1997-01-10 1999-07-01 Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser NO993275L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (en) 1997-01-10 1998-01-09 Methods of therapeutic administration of anti-cd40l compounds

Publications (2)

Publication Number Publication Date
NO993275D0 true NO993275D0 (no) 1999-07-01
NO993275L NO993275L (no) 1999-09-09

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993275A NO993275L (no) 1997-01-10 1999-07-01 Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser

Country Status (21)

Country Link
US (2) US20020071840A1 (no)
EP (1) EP0966302B1 (no)
JP (1) JP2001508450A (no)
KR (2) KR20000070035A (no)
CN (1) CN1248921A (no)
AT (1) ATE356634T1 (no)
AU (1) AU721697B2 (no)
BR (1) BR9807471A (no)
CA (1) CA2277223A1 (no)
CZ (1) CZ244399A3 (no)
DE (1) DE69837322T2 (no)
EA (1) EA001426B1 (no)
EE (1) EE9900275A (no)
HK (1) HK1024424A1 (no)
IL (1) IL130785A0 (no)
IS (1) IS5101A (no)
NO (1) NO993275L (no)
NZ (1) NZ337073A (no)
PL (1) PL193966B1 (no)
TR (1) TR199902192T2 (no)
WO (1) WO1998030241A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EA002549B1 (ru) * 1997-05-17 2002-06-27 Байоджен, Инк. Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантата
EE9900587A (et) * 1997-06-20 2000-08-15 Biogen, Incorporated CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul
MXPA01002898A (es) * 1998-09-21 2002-06-04 Genetics Inst Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
US20030170231A1 (en) * 2000-03-06 2003-09-11 Toshihiko Yamauchi Remedies and preventives for antiphospholipid antibody syndrome
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
IL152450A0 (en) 2000-05-12 2003-05-29 Genzyme Corp COMPOUNDS HAVING TNF-alpha SIGNAL MODULATING ACTIVITY
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
JP2012511014A (ja) 2008-12-05 2012-05-17 エイエルエス・セラピー・デベロップメント・インスティテュート 神経変成疾患を治療する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
IL110852A (en) * 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
NZ273207A (en) * 1993-09-02 1997-09-22 Dartmouth College Igg antibodies gp39 (cd40)
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PT751781E (pt) * 1993-12-23 2004-09-30 Nat Inst Of Health As Repr By Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
CN1248921A (zh) 2000-03-29
EA199900633A1 (ru) 2000-02-28
CZ244399A3 (cs) 1999-10-13
PL334500A1 (en) 2000-02-28
JP2001508450A (ja) 2001-06-26
NO993275L (no) 1999-09-09
EP0966302A1 (en) 1999-12-29
WO1998030241A1 (en) 1998-07-16
KR20050088494A (ko) 2005-09-06
KR100632846B1 (ko) 2006-10-16
HK1024424A1 (en) 2000-10-13
NZ337073A (en) 2001-01-26
DE69837322T2 (de) 2007-11-22
ATE356634T1 (de) 2007-04-15
US20050158314A1 (en) 2005-07-21
AU5735398A (en) 1998-08-03
KR20000070035A (ko) 2000-11-25
CA2277223A1 (en) 1998-07-16
PL193966B1 (pl) 2007-04-30
US20020071840A1 (en) 2002-06-13
IS5101A (is) 1999-06-30
EP0966302B1 (en) 2007-03-14
EA001426B1 (ru) 2001-02-26
BR9807471A (pt) 2000-03-21
DE69837322D1 (de) 2007-04-26
IL130785A0 (en) 2001-01-28
EE9900275A (et) 2000-02-15
AU721697B2 (en) 2000-07-13
TR199902192T2 (xx) 1999-12-21

Similar Documents

Publication Publication Date Title
NO993275L (no) Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
ES2191069T3 (es) Diaril-2-(5h)-furanonas como inhibidores de cox-2.
DE69514813T2 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
DK0900200T3 (da) Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
IL192287A0 (en) Pharmaceutical compositions and methods for use
PT1039900E (pt) Agentes terapeuticos
DE69625682T2 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
HK1043315A1 (en) Triazineone compounds for treating diseases due tosarcosystis, neospora and toxoplasma.
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE293602T1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
EA200200846A1 (ru) Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором
LV12459A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application